Anaemia of Chronic Kidney Disease: What We Know Now

Main Article Content

Anoushka R. Krishnan
Debbie Trinder
Anita C.G. Chua
Aron Chakera
Grant A. Ramm
John K. Olynyk

Abstract

Our understanding of the pathophysiology of the anaemia of chronic kidney disease (CKD) has improved considerably in the last decade with the discovery of the iron regulatory peptide hepcidin. Reduced clearance of hepcidin and the presence of a chronic inflammatory state contribute to elevated hepcidin levels in kidney disease. The recent discovery of the various factors and signalling pathways regulating hepcidin has opened up an exciting avenue for research into the development of newer agents that could treat anaemia of CKD. This review highlights our current understanding of iron metabolism in health, the regulators of hepcidin, issues associated with the current available therapies for the treatment of anaemia in CKD and potential novel therapies that could be available in the near future targeting the various factors that regulate hepcidin.

Downloads

Download data is not yet available.

Article Details

How to Cite
Krishnan, A. R., Trinder, D., Chua, A. C., Chakera, A., Ramm, G. A., & Olynyk, J. K. (2017). Anaemia of Chronic Kidney Disease: What We Know Now. Journal of Renal and Hepatic Disorders, 1(1), 11-19. https://doi.org/10.15586/jrenhep.2017.5
Section
Review Nephrology
Author Biographies

Anoushka R. Krishnan, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia

Nephrology trainee

Debbie Trinder, School of Medicine and Pharmacology, University of Western Australia, Fiona Stanley Hospital, Murdoch, Western Australia, Australia Harry Perkins Institute of Medical Research, Murdoch, Western Australia, Australia

Associate Professor

Head, Centre for Iron Metabolism and Liver Disease Research

Aron Chakera, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia

Associate Professor, Nephrology

Head, Renal Translational Research, Harry Perkins Institute 

Grant A. Ramm, QIMR Berghofer Medical Research Institute, Brisbane, Queensland and Faculty of Medicine and Biomedical Sciences, The University of Queensland, Brisbane, Queensland Australia

Professor

Department Coordinator, Cell and Molecular Biology Group Leader, Hepatic Fibrosis

John K. Olynyk, School of Medicine and Pharmacology, University of Western Australia, Fiona Stanley Hospital, Murdoch, Western Australia, Australia and Department of Gastroenterology, Fiona Stanley Hospital, Perth, Western Australia, Australia

Professor of Translational Medicine Head of Gastroenterology & Hepatology